Rise Advisors’s Viking Therapeutics VKTX Stock Holding History

Rise Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42	Closed	-$1.1K	–	1377
2025 Q3	$1.1K	Sell	42 -150	-78%	-$4.47K	﹤0.01%	1267
2025 Q2	$5.09K	Sell	192 -8	-4%	-$211	﹤0.01%	1156
2025 Q1	$4.83K	Buy	+200	New	+$6.32K	﹤0.01%	1156

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rise Advisors's VKTX Position: Q4 2025 in Review

Rise Advisors sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 42 shares — an estimated $1.1K sold.

Rise Advisors first reported a position in VKTX in Q1 2025 and held it in 3 quarters. The position peaked at $5.09K in Q2 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Rise Advisors reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 42 Viking Therapeutics shares in Q4 2025, an estimated $1.1K.
Rise Advisors first reported a position in Viking Therapeutics in Q1 2025 and held it in 3 quarters.
Rise Advisors's Viking Therapeutics position peaked at $5.09K in Q2 2025.
427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.